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Abstract 
Liposomes modified with the uronic acid derivative palmityI-D-glucuronide (PGIcUA) have a long-circulation time and tend to 
accumulate in the tumors of tumor-bearing mice. Taking advantage of this character, we investigated the therapeutic effect of vincristine 
(VCR) encapsulated in liposomes containing PGIcUA (dipalmitoylphosphatidylcholine/cholesterol/PGIcUA = 4:4:1 as a molar ratio) on 
tumor-bearing mice. VCR was loaded into liposomes by a remote loading method, and then free or liposomal VCR was injected 
intravenously into BALB/c mice bearing Meth A sarcoma implanted subcutaneously 5 days before hand. Single-dose administration of
VCR (3.0 mg/kg) in PGlcUA-liposomes ignificantly suppressed tumor growth, and prolonged the survival time (T/C = 1.37). 
Furthermore, two-dose administration f the liposomes cured one third of the animals. The therapeutic effect of PGlcUA-liposomes was 
greater than that of control iposomes containing dipalmitoylphosphatidylglycerol instead of PGIcUA. PGIcUA- liposomes might thus be 
a useful tool for delivering antitumor agents to tumor tissues. 
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1. Introduction 
Liposomes can be used as ideal drug carriers in the field 
of DDS, and many previous tudies have demonstrated the 
enhanced efficacy of encapsulated drugs and the reduction 
of the side effects of drugs so entrapped [1-4]. They have 
been effectively used especially as carriers of antitumor 
drugs, since liposomes can encapsulate and deliver the 
large amount of drugs to the tumor tissues, and can reduce 
the side effect of the drugs which is usually severe prob- 
lem especially for antitumor agents. Conventional lipo- 
somes which are not specifically modified for obtaining 
long-circulating character, however, have a limitation, since 
they tend to be trapped by reticuloendothelial system 
(RES). Many attempts have been made to avoid the RES- 
trapping of liposomes and to get the longer half-lives of 
liposomes in the bloodstream, by the modification of lipo- 
somal surface. Successful results were obtained by the 
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modification of liposomes with monosialoganglioside GMI 
[5,6] poly(ethylene glycol) (PEG) [7-10] and so on, al- 
though GMI modification was revealed to be effective 
only in mice and not in rats [11] nor rabbits [12]. We 
previously reported that the modification of liposomes 
with a glucuronic acid derivative, palmityl-D-glucuronide 
(PGIcUA), resulted in liposomes with a longer circulation 
time in the bloodstream of rats and mice [13,14]. Further- 
more, a remarkable accumulation of PGlcUA-liposomes in
tumor tissues in tumor-bearing mice, maybe due to passive 
targeting, was observed [14.15]. In the present study, we 
investigated the therapeutic effect of VCR encapsulated in 
PGlcUA-liposomes by use of Meth A sarcoma-bearing 
mice. 
2. Materials and methods 
2.1. Materials 
Dipalmitoylphosphatidylcholine (DPPC) and dipalmi- 
toylphosphatidylglycerol (DPPG) were the products of 
Nippon Fine Chemical (Takasago. Hyogo, Japan). Choles- 
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terol (Chol), vincristine (VCR) and octylglucoside were 
obtained from Sigma (St. Louis, MO). [G-3H]Vincristine 
sulphate was purchased from Amersham (Buckingham- 
shire, UK). Palmityl-D-glucuronide (/3-hexadecyl-D- 
glucuronide, PGlcUA) was synthesized as described previ- 
ously [ 13]. 
2.2. Liposomalization of VCR 
Liposomes were prepared according to the method de- 
scribed previously [14]. In brief, DPPC and Chol with 
PGlcUA or DPPG (4:4:1 as a molar ratio) were dissolved 
in chloroform, dried under reduced pressure and stored in 
vacuo for at least 1 h. Resulting thin lipid film was 
hydrated with 0.3 M sodium citrate, pH 4.0. Then lipo- 
somes were subjected to freeze-thawing for three cycles 
using liquid nitrogen, and extruded through a polycarbon- 
ate membrane filter with a 100-nm pore size (Nucleopore, 
Costar, Cambridge, MA). The size distribution of lipo- 
somes was determined by dynamic light scattering with a 
Submicron Particle Analyzer (Nicomp Model 370) after 
preparing liposomes with the same procedures. Volume- 
weighted particle sizes of PGlcUA- and DPPG-liposomes 
were 123 and 117 nm with standard eviations of 45 and 
36 rim, respectively, and number-weighted particle sizes of 
those were 69 and 77 nm with standard eviations of 21 
and 28 nm, respectively. VCR-loading into liposomes were 
performed by a modification of the remote loading method 
developed by Mayer et al. [16]. Briefly, the pH outside of 
the liposomes was adjusted to 7.5 by the addition of 
sodium bicarbonate, and the liposomal solution was incu- 
bated with VCR (VCR/liposomal lipids = 0.2:1 as a 
weight ratio) for 1 h at 60°C. Encapsulation efficiency was 
more than 90% as determined by the absorbance at297 nm 
in the presence of 0.7% octylglucoside after separation of 
free and liposomal VCR by centrifugation of the liposomal 
suspension (100 000 × g for 5 rain with Hitachi, 
CSI20EX). Untrapped VCR was removed by centrifuga- 
tion at 100000Xg for 5 rain. Liposomal pellet was 
resuspended in saline appropriately. 
2.3. Assay of liposomal stability 
VCR-encapsulated liposomes composed of DPPC, Chol, 
and PGIcUA or DPPG (4:4:1 as a molar ratio) were 
incubated in phosphate-buffered saline, pH 7.2, or in 90% 
fetal bovine serum (Hezleton Biologics, Lenexa, KS) at 
37°C. At selected times, 400 pA of sample was removed 
and centrifuged at 100000 × g for 5 min to pellet the 
liposomes. An aliquot of the supernatant was collected and 
its VCR content was determined photometrically. 
obtain 5. 10 6 cells/ml suspension. Then 0.2 ml of the 
suspension was carefully injected s.c. into the posterior 
flank of 5-week-old BALB/c  male mice (n = 5). Lipo- 
somes encapsulating cold and a trace of 3H-labeled VCR 
were prepared just prior to administration. Liposomal and 
free VCR (1.5 mg/kg  as VCR, 74 kBq/mouse) were i.v. 
injected into Meth A sarcoma bearing-mice. Mice were 
killed with ether anesthesia for collection of blood 6 h 
after injection, and the radioactivity in the plasma was 
measured after centrifugation of the blood. The lungs, 
heart, liver, spleen, kidneys and tumor were then removed 
after bleeding, washed with saline and weighed. About 100 
mg of each tissue, or the whole tissue when it weighed less 
than 100 mg, were minced and solubilized in 1 ml of 
Solvable (NEN Research Products, Boston, MA) overnight 
at 40°C. After treatment with hydrogen peroxide, a 
Hionic-Fluor (Packard Japan, Tokyo, Japan) scintillation 
cocktail was added and the radioactivity in each sample 
was determined in a liquid scintillation counter (Aloka, 
LSC-3500). The total blood volume (7.3% of body weight) 
and correction factors for the blood content of various 
tissues were determined as described previously by use of 
51Cr-labeled erythrocytes [17]. 
2.5. Therapeutic experiment and statistical analysis 
Meth A sarcoma (1 • 10 6 cells/0.2 ml) was carefully 
injected s.c. into the posterior flank of five-week-old 
BALB/c male mice (n = 10-12). Liposomes encapsulat- 
ing VCR were prepared just prior to administration. Lipo- 
somes and free drugs were i.v. injected with single- or 
two-dose administration into Meth A sarcoma bearing- 
mice. Mouse weight and tumor volume were monitored 
every day after administration of drugs. Tumor volume 
was determined by measuring two bisecting diameters of 
each tumor with slide calipers, and calculated by the 
formula 0.4(a × b 2) where 'a '  is the largest and ~b' the 
smallest diameter. Tumor volume obtained by this mea- 
surement is known to correlate well with actual tumor 
weight (r  = 0.980). Variance in a group was evaluated by 
the F-test, and differences in mean tumor volume were 
evaluated by Student's t-test. Differences were considered 
significant when the P value of comparison was less than 
0.05. 
3. Results 
3.1. Stabilio, of VCR-encapsulated liposomes 
2.4. Study on biodistribution of liposomal VCR 
Meth A sarcoma grown in the ascites of BALB/c mice 
under an appropriate schedule was diluted with saline to 
At first, we examined the stability of PGlcUA- and 
DPPG-liposomes containing VCR in the presence and 
absence of serum (Fig. 1). Both liposomes were quite 
stable in phosphate-buffered saline and in serum. These in 
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Fig. 1. VCR release from long-circulating liposomes in serum. VCR-en- 
capsulated liposomes composed of DPPC/Chol/PGIcUA (4:4:1. closed 
symbols) or DPPC/Chol/DPPG (4:4:1, open symbols) were incubated in 
90% serum (circles) or in phosphate-buffered saline (triangles) at 37°C 
for the indicated times. The released VCR was determined as described in 
Section 2. 
vitro data suggest that VCR will not leak out during 
circulation. 
3.2. Therapeutic effect of liposomal VCR after single-dose 
administration 
Therapeutic effect was determined by the suppression 
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Fig. 2. Suppression of tumor growth by treatment with liposomal VCR. 
Meth A sarcoma (1.106 cells/0.2 ml) was carefully implanted subcuta- 
neously into the posterior flank of 5-week-old BALB/c male mice. These 
mice (ten per group) were injected i.v. with saline (O), 1.5 mg/kg free 
VCR (O), 3.0 mg/kg VCR encapsulated in DPPG-liposomes ( • ), or 3.0 
mg/kg VCR in PGlcUA-liposomes (11), at day 5. The tumor volume 
was determined at the indicated ays as described in Section 2. S.D. bars 
are shown only for the last points for the sake of graphic larity. 
Table 1 
Survival time of Meth A sarcoma-bearing mice treated with VCR-en- 
capsulated long-circulating liposomes 
Treatment Mean survival T/C 
(days _+ S.D.) 
Control 31.8 _+ 2.4 1.00 
Free VCR ( 1.5 mg/kg) 35.3 _+ 6.1 1.11 
DPPG-liposomes (3.0 mg/kg) 38.6 _+ 1.1 1.21 
PGlcUA-liposomes (3.0 mg/kg) 43.6 + 4.3 " 1.37 
• Significantly different from others. 
of tumor growth and the increase in life time of tumor- 
bearing mice after treatment with free or l iposomal VCR. 
The treatment was performed at day 5 after tumor implan- 
tation. The dose of  1.5 mg/kg  was used for free VCR and 
3 mg/kg  dose (15 mg/kg  as l iposomal lipids) was for 
l iposomal VCR, since 3 mg/kg  free VCR was toxic to the 
animal whereas l iposomal formulation could reduce the 
acute toxicity (data not shown). As shown in Fig. 2, 
administration of  VCR-encapsulated PGlcUA- l iposomes 
was most efficient for suppressing tumor growth. Survival 
time and T /C  are presented in Table 1. PGlcUA- l ipo-  
somes with encapsulated VCR were the most efficient for 
prolonging survival time of tumor bearing mice. 
3.3. Biodistribution of  liposomal VCR in Meth-A- 
sarcoma-bearing mice 
To examine the long-circulating activity of PGIcUA 
l iposomes, the biodistribution of free and l iposomal VCR 6 
h after injection was determined by use of  radioactive 
VCR. As shown in Fig. 3, the amounts of  VCR remained 
in plasma and accumulated in tumor were extremely higher 
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Fig. 3. Biodistribution of liposomal VCR in tumor-bearing mice 6 h after 
i.v. administration. Free [3H]VCR (open bars), or liposomes encapsulat- 
ing [3H]VCR (PGlcUA-liposomes. closed bars: DPPG-liposomes, hatched 
bars) were injected into a tail vein in Meth-A-sarcoma-bearing mice (5 
per group). The animals were killed under ether anesthesia 6 h after 
administration and the biodistribution of [3H]VCR was determined as 
described in Section 2. 
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when both liposomal formulations were injected than those 
after the administration of free VCR. Furthermore, the 
higher radioactivity was detected in tumor tissues by use 
of PGlcUA-l iposomes than by use of DPPG-liposomes, 
consistent with the previous observation for l iposomal 
biodistribution [14]. 
3.4. Therapeutic effect of liposomal VCR after two-dose 
administration 
Next we examined the therapeutic effect of liposomal 
VCR after two-dose administration at days 5 and 12 after 
tumor implantation. As shown in Fig. 4, two-dose adminis- 
tration was more efficient than single-dose administration 
especially by use of liposomal formulation. The result 
indicates that liposomal formulation is efficient for sup- 
pressing grown tumor whereas free drug is inefficient for 
suppressing grown one. Especially, VCR-encapsulated 
PGlcUA-l iposomes which are long-circulating liposomes 
were efficient due to the high accumulation in grown 
tumor. 
We also determined the side effect of VCR in liposomal 
formulation. Fig. 5 shows the change in body weight of 
mice, which is one of criteria of side effect, after adminis- 
tration of drugs. Obvious weight loss was observed in mice 
injected with 1.5 mg/kg  free VCR, which is slightly lower 
than the LDs0, and with 3.0 mg/kg  liposomal VCR. The 
toxicity of VCR was, however, reduced by the liposomal 
formulation, since none of the mice died after treatment 
with 3.0 mg/kg  VCR by the liposomal formulation. 
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Fig. 4. Suppression f tumor growth by two-dose treatment with liposo- 
mal VCR. Meth A sarcoma implantation a d tumor volume determination 
was performed as described in the legend of Fig. 2. These mice (12 per 
group except for control iposomes in which 10 mice were used) were 
injected i.v. with saline (O), 1.5 mg/kg free VCR (A), 3.0 mg/kg VCR 
encapsulated in DPPG-liposomes (•),  or 3.0 mg/kg VCR in PGlcUA- 
liposomes ( I ) ,  at days 5 and 12 indicated by arrows. S.D. bars are 
shown only for the last points for the sake of graphic larity. 
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Fig. 5. Effect of liposomal VCR on the body weight of tumor-bearing 
mice. Meth A sarcoma-bearing mice were treated with saline (©), 1.5 
mg/kg free VCR (0), 3.0 mg/kg VCR encapsulated in DPPG-lipo- 
somes ( • ), or 3.0 mg/kg VCR in PGlcUA-liposomes ( • ), at days 5 and 
12 as described in the legend of Fig. 4. 
Fig. 6 shows the survival time of treated animals. 
PGlcUA-l iposomes encapsulating VCR were the most effi- 
cient for prolonging survival time of tumor bearing mice, 
and 33% of the animals were cured. These mice were 
apparently tumor free and remained alive throughout the 
experimental period (more than 180 days). Mean survival 
of the other 67% of the VCR-PGlcUA-l iposome-treated 
animals was 50.9 + 17.0 days, which was 1.5-fold longer 
than the survival of the saline treatment group (33.7 + 3.2 
days). 
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Fig. 6. The survival of Meth A-bearing mice by treatment with VCR 
encapsulated in long-circulating liposomes. Mice implanted s.c. with 
Meth A sarcoma (1.106 cells) were injected i.v. on days 5 and 12 as 
described in the legend of Fig. 4 with saline (O), 1.5 mg/kg free VCR 
(O), 3.0 mg/kg VCR encapsulated in DPPG-liposomes (A), or 3.0 
mg/kg VCR in PGlcUA-liposomes (•).  The mean survival time (days) 
was 33.7+3.2, 40.4+7.7, 42.6+7.4, and 50.9+7.0, respectively. 
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4. Discussion Acknowledgements 
Liposomalization f antitumor drugs has been shown to 
reduce the side effect of the drugs and to enhance their 
therapeutic efficacy [1-4]. Since conventional iiposomes 
tend to be trapped in the reticuloendothelial system (RES), 
avoidance of the RES-trapping in order to prolong the 
circulation time of liposomes has been attempted. For this 
purpose, we synthesized a glucuronate derivative, 
palmityl-D-glucuronide (PGlcUA), that is rather easily pre- 
pared and readily incorporated into the liposomal bilayer 
[13]. These long-circulating liposomes howed further ad- 
vantage for tumor therapy; they accumulate passively in 
tumor tissues, since the vasculature in the tumor tissues is 
leaky enough to extravasate small-sized liposomes. 
This passive-targeting character of long-circulating lipo- 
somes to tumor tissues might be useful for tumor imaging 
[15] and for cancer therapy, since there is a positive 
correlation between the circulation time of liposomes and 
their accumulation into tumor tissues. In fact, it was 
demonstrated that anthracyclines, such as doxorubicin, en- 
capsulated in long-circulating liposomes were selectively 
delivered to the tumor tissues than free drugs. Therefore, a
significant enhancement of the antitumor activity was 
achieved by such long-circulating liposomes [18-20] in- 
cluding PGlcUA-liposomes [17]. Furthermore, PEG-coated 
long-circulating liposomes containing doxorubicin were 
effective in suppressing spontaneous metastasis [21,22]. 
VCR was also encapsulated into PEG-coated long-cir- 
culating liposomes which showed a marked therapeutic 
efficacy on mammary carcinoma-bearing mice [23]. Simi- 
larly, GMl-modified liposomes were revealed to be effec- 
tive against P388 tumors [24]. In the present study shows 
the obvious therapeutic effect of VCR encapsulated in
PGlcUA-liposomes on tumor-bearing mice. Especially 
when liposomal VCR was administered twice at days 5 
and 12, a significant therapeutic effect of VCR was obvi- 
ously observed with the long-circulating liposomes than in 
the case of free-VCR treatment or treatment with VCR 
encapsulated in conventional liposomes. These findings 
suggest that the efficacy of VCR in long-circulating lipo- 
somes comes from the tumor accumulation of the lipo- 
somes. Furthermore, the reduction of toxic effect of VCR 
in terms of liposomal formulation allowed us to use higher 
doses of the drugs to be given. This also may cause 
significant therapeutic efficacy by liposomal formulation. 
In conclusion, VCR encapsulated in PGlcUA-liposomes 
showed enhanced therapeutic efficacy in tumor-bearing 
mice in comparison with the free VCR or VCR encapsu- 
lated in conventional liposomes. These effect might be 
caused by the intense accumulation of long-circulating 
PGlcUA-liposomes in tumor tissues. Therefore, the long- 
circulating liposomes presented here may be practically 
useful for delivering anticancer drugs. 
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